The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Hodgkin lymphoma highlights at ASH 2022 and future outlooks
In this video, John Kuruvilla, MD, FRCPC, Princess Margaret Cancer Centre, Toronto, Canada, shares some highlights in Hodgkin lymphoma (HL) presented at the ASH 2022 Annual Meeting. Dr Kuruvilla comments on the overall survival (OS) data recently reported in the ECHELON-1 trial (NCT01712490) and the updated results of the RATHL trial (CRUK/07/033), and concludes by discussing future considerations for the treatment of HL. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
